Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990798470> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2990798470 abstract "Background: The risk of short-term deterioration, assessed by the CID composite measure, is reduced with dual vs mono bronchodilators in inhaled corticosteroid (ICS)-free symptomatic patients with COPD. It is unclear if this protection alters with baseline severity of COPD. Aims: This pre-specified secondary analysis of the Early MAXimization of bronchodilation for improving COPD stability (EMAX) trial compared CID risk in the ITT population and in severity subgroups with a baseline GOLD spirometric grade 3 (FEV1 30–50% predicted) or COPD Assessment Test (CAT) score ≥20. Methods: This 24-week, double-blind, parallel-group trial randomised patients to umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg QD, UMEC 62.5 µg QD, or salmeterol (SAL) 50 µg BID. Risk of a first CID was assessed using 3 definitions of CID (Figure). Results: In the ITT population and subgroups, CID risk was lower with UMEC/VI vs UMEC or SAL for all CID definitions, except in one instance (Figure). This protection was numerically higher in the GOLD 3 subgroup regardless of CID definition, but not in the CAT ≥20 subgroup. Conclusions: In symptomatic ICS-free patients at low exacerbation risk, UMEC/VI reduced CID risk vs UMEC and SAL. Compared with the ITT population, this protection was greater in patients with more severe airflow limitation but not with more symptoms. Funding: GSK (study 201749; NCT03034915)" @default.
- W2990798470 created "2019-12-05" @default.
- W2990798470 creator A5000958944 @default.
- W2990798470 creator A5025257736 @default.
- W2990798470 creator A5025358852 @default.
- W2990798470 creator A5042776900 @default.
- W2990798470 creator A5046338978 @default.
- W2990798470 creator A5047445014 @default.
- W2990798470 creator A5052171516 @default.
- W2990798470 creator A5059684830 @default.
- W2990798470 creator A5077397101 @default.
- W2990798470 creator A5087152114 @default.
- W2990798470 date "2019-09-28" @default.
- W2990798470 modified "2023-09-26" @default.
- W2990798470 title "Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial" @default.
- W2990798470 doi "https://doi.org/10.1183/13993003.congress-2019.pa2475" @default.
- W2990798470 hasPublicationYear "2019" @default.
- W2990798470 type Work @default.
- W2990798470 sameAs 2990798470 @default.
- W2990798470 citedByCount "0" @default.
- W2990798470 crossrefType "proceedings-article" @default.
- W2990798470 hasAuthorship W2990798470A5000958944 @default.
- W2990798470 hasAuthorship W2990798470A5025257736 @default.
- W2990798470 hasAuthorship W2990798470A5025358852 @default.
- W2990798470 hasAuthorship W2990798470A5042776900 @default.
- W2990798470 hasAuthorship W2990798470A5046338978 @default.
- W2990798470 hasAuthorship W2990798470A5047445014 @default.
- W2990798470 hasAuthorship W2990798470A5052171516 @default.
- W2990798470 hasAuthorship W2990798470A5059684830 @default.
- W2990798470 hasAuthorship W2990798470A5077397101 @default.
- W2990798470 hasAuthorship W2990798470A5087152114 @default.
- W2990798470 hasConcept C126322002 @default.
- W2990798470 hasConcept C1862650 @default.
- W2990798470 hasConcept C2776780178 @default.
- W2990798470 hasConcept C2777014857 @default.
- W2990798470 hasConcept C2908647359 @default.
- W2990798470 hasConcept C71924100 @default.
- W2990798470 hasConcept C99454951 @default.
- W2990798470 hasConceptScore W2990798470C126322002 @default.
- W2990798470 hasConceptScore W2990798470C1862650 @default.
- W2990798470 hasConceptScore W2990798470C2776780178 @default.
- W2990798470 hasConceptScore W2990798470C2777014857 @default.
- W2990798470 hasConceptScore W2990798470C2908647359 @default.
- W2990798470 hasConceptScore W2990798470C71924100 @default.
- W2990798470 hasConceptScore W2990798470C99454951 @default.
- W2990798470 hasLocation W29907984701 @default.
- W2990798470 hasOpenAccess W2990798470 @default.
- W2990798470 hasPrimaryLocation W29907984701 @default.
- W2990798470 hasRelatedWork W1553966959 @default.
- W2990798470 hasRelatedWork W1768394073 @default.
- W2990798470 hasRelatedWork W2006528231 @default.
- W2990798470 hasRelatedWork W2527797620 @default.
- W2990798470 hasRelatedWork W2556532240 @default.
- W2990798470 hasRelatedWork W2561725420 @default.
- W2990798470 hasRelatedWork W2780634547 @default.
- W2990798470 hasRelatedWork W2808699155 @default.
- W2990798470 hasRelatedWork W2809579464 @default.
- W2990798470 hasRelatedWork W2891291416 @default.
- W2990798470 hasRelatedWork W2894623749 @default.
- W2990798470 hasRelatedWork W2905799898 @default.
- W2990798470 hasRelatedWork W2936497717 @default.
- W2990798470 hasRelatedWork W2946127958 @default.
- W2990798470 hasRelatedWork W2989553888 @default.
- W2990798470 hasRelatedWork W2990901894 @default.
- W2990798470 hasRelatedWork W2993660735 @default.
- W2990798470 hasRelatedWork W3033269533 @default.
- W2990798470 hasRelatedWork W3092513407 @default.
- W2990798470 hasRelatedWork W3156817660 @default.
- W2990798470 isParatext "false" @default.
- W2990798470 isRetracted "false" @default.
- W2990798470 magId "2990798470" @default.
- W2990798470 workType "article" @default.